# Single Dose Study of ANX005 in Healthy Volunteers

> **NCT03010046** · PHASE1 · TERMINATED · sponsor: **Annexon, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Safety and Tolerability in Healthy Volunteers

## Interventions

- **DRUG:** ANX005
- **DRUG:** IVIg
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03010046
- **Lead sponsor:** Annexon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** ANX005 well tolerated at doses studied; study discontinued and initiated in patient population
- **Last updated:** 2020-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03010046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03010046, "Single Dose Study of ANX005 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03010046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*